Study on mental health and immune therapy for stomach cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how psychological distress relates to immune checkpoint inhibitors in people with stomach cancer. It may help understand if emotional well-being affects treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with stomach adenocarcinoma (a type of stomach cancer) through a biopsy
- Your doctor has decided you need immune therapy before surgery to remove the tumor
- You are willing and able to have the tumor removed with surgery after immune therapy
- You do not have serious mental illness, active infections, or autoimmune diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination treatment for advanced or metastatic stomach cancer (that is MSS/pMMR and HER2-negative) that has not been treated before. The treatment combines a short course of radiation (targeted to lymph nodes) with first-line therapy and a PD-1 inhibitor (a type of immunotherapy) to see if it can help control the cancer and improve outcomes.
This study looks at how emotional distress before treatment affects how well the tumor responds to chemotherapy and surgery in people with stomach or gastroesophageal junction cancer. It may help understand if mental health impacts treatment outcomes.
This study looks at how the immune system behaves in stomach or lower esophagus cancer before standard (planned) surgery. It may help researchers understand which immune features relate to outcomes and treatment response.
This study looks at how psychological stress affects treatment success and long-term outcomes in people with stomach cancer. It includes three different groups of patients at various stages of the disease.
This trial studies whether blood tests before treatment can predict side effects from immunotherapy (PD-1/PD-L1 inhibitors) in people with gastric cancer. If you are about to start this type of treatment, your participation could help doctors manage side effects better.
This study tests a program that uses smart technology to provide personalized symptom management education and home-based exercises for people with advanced stomach cancer receiving immunotherapy. The goal is to help reduce frailty and treatment side effects, and improve quality of life.
Hear when a new Gastric Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.